Document:

Exhibit 10.3 

 

AGREEMENT

 

This Agreement (the
 “Agreement”), dated as of December 23, 2020, is entered into by and between Q BIOMED INC., a company incorporated
under the laws of the State of Nevada (the “Company”), and YA II PN, LTD. (the “Holder”).

 

BACKGROUND

 

		(A)	The Board of Directors of the Company has authorized the issuance of a series of preferred stock
of the Company consisting of 1,000,000 shares, $0.001 par value per share, designated as “Series B Convertible Preferred
Stock” (Each such share, a “Series B Preferred Share”) which shall be convertible into Common Stock pursuant
to the terms and conditions of the Certificate of Designations, Powers, Preferences and other rights of Preferred Stock and Qualification,
Limitations and Restrictions thereof of Series B Convertible Preferred Shares (“Certificate of Designations”).

 

		(B)	As of the date hereof, the Holder is the holder of 503,134 Series B Preferred Shares.

 

		(C)	Pursuant to the Certificate of Designations, the Company shall not incur certain Indebtedness without
the consent of the holders of the Series B Preferred Shares.

 

		(D)	The parties desire to enter into this Agreement to pursuant to which, on the terms and conditions
set forth herein, the Holder shall consent to the occurrence of certain Indebtedness of the Company and the Company shall modify
the Conversion Price with respect to a portion of the Holder’s Series B Preferred Shares.

 

NOW, THEREFORE,
in consideration of the foregoing recitals and representations, warranties and covenants herein set forth, the parties hereto agree
as follows:

 

1.             Definitions
and interpretation

 

1.1       Capitalized
terms not otherwise defined herein shall have the meanings set forth in the Certificate of Designations.

 

2.             Amendments
to the Convertible Debentures

 

In consideration of
the mutual promises set forth herein, the parties hereto agree as follows:

 

2.1      Conversion
Price. In accordance with clause (iii) of the definition of “Conversion Price” set forth in the Certificate of
Designations, the Conversion Price with respect to the conversion of the next 50,000 Series B Preferred Shares (i.e., shares with
a total Liquidation Value of $500,000) converted by the Holder shall be equal to $0.75.

 

2.2      Consent
of Holder. The Holder, as the sole holder of all of the outstanding Series B Preferred Shares, hereby consents to the Company
incurring additional Indebtedness in the amount of $500,000 through the issuance of convertible debentures.

 

    

     

    

 

3.             Representations
and warranties 

 

		3.1	Each party to this Agreement represents and warrants to the other as of the date of this Agreement
that:

 

(a)       it
has the requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated by
this Agreement;

 

(b)       it
has taken all necessary corporate actions to authorize the execution, delivery and performance of this Agreement and no further
action is required by it, its Board of Directors or managers or its stockholders or members in connection therewith; and

 

(c)       the
obligations assumed by it in this Agreement are legal, valid, and enforceable obligations binding on it in accordance with its
terms.

 

3.2       The
Company represents and warrants to the Holder that any shares of Common Stock that may be issued upon conversion of the Series
B Preferred Shares as a result of this Agreement have been duly authorized and shall be validly issued and duly authorized.

 

4.             Counterparts
and delivery

 

This Agreement may
be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the
parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail
delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

 

5.             Governing
law

 

This Agreement shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
the Securities Purchase Agreement dated April 6, 2020 and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other
manner permitted by law.

 

[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK]

 

    

     

    

 

IN WITNESS WHEREOF,
the Company and the Holder have caused this Agreement to be signed by their duly authorized officers.

 

		Q BIOMED INC.
	 	 	 
	 	By:	/s/ Denis Corin
	 	 	Name: Denis Corin
	 	 	Title:   President

 

	 	YA II PN, LTD. 
	 	 
	 	By:	Yorkville Advisors Global, LP
	 	Its:	 Investment Manager

 

	 	By:	Yorkville Advisors Global II LLC
	 	Its:	General Partner

 

	 	By:	/s/ Matt Beckman
	 	Name:	Matt Beckman
	 	Title:	MemberExhibit 10.4

 

SECURITIES PURCHASE AGREEMENT

 

THIS SECURITIES
PURCHASE AGREEMENT (this "Agreement"), dated as of October ___, 2020, is between Q BIOMED INC., a
company incorporated under the laws of the State of Nevada, with headquarters located at 366 Madison Ave, 3rd Floor,
New York, NY 10017 (the "Company"), and each of the investors that has signed this Agreement (individually, a
 "Buyer" and collectively the "Buyers").

 

WITNESSETH

 

WHEREAS, the
Company and each Buyer desire to enter into this transaction for the Company to sell and the Buyers to purchase the Units (as defined
below) pursuant to an exemption from registration pursuant to Section 4(2), Rule 506 of Regulation D ("Regulation
D") and/or Regulation S as promulgated by the U.S. Securities and Exchange Commission (the "SEC") under
the Securities Act of 1933, as amended (the "Securities Act");

 

WHEREAS, the
parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the Buyer(s),
as provided herein, and the Buyer(s) shall purchase up to an aggregate of 2,000,000 units and which may be increased upon
approval of the Company's Board of Directors), each a “Unit”, consisting of (i) one (1) share of the
Company's common stock, par value $0.001 (the "Common Stock") and (ii) one (1) warrant, the form of
which is attached hereto as Exhibit A (the "Warrants"), to purchase a share of Common Stock at an
exercise price of $1.50 (such shares issuable upon exercise, the "Warrant Shares" and together with the Units,
the Common Stock and the Warrants, the “Securities”), for a per Unit purchase price of $0.90 (the "Purchase
Price") in the respective amounts set forth on each Buyer's signature page (the "Subscription Amount");

 

WHEREAS, the
parties hereto contemplate that this Agreement may be entered into by and between the Company and each Buyer on multiple dates
(or all Buyers on one date) with the obligations incurring to each such Buyer and the Company with respect to such Buyer at the
time of such entry (each such event, a “Closing”);

 

AGREEMENT

 

NOW, THEREFORE,
in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and each Buyer hereby agree as follows:

 

I.              PURCHASE
AND SALE OF UNITS.

 

(a)            Purchase
of Units. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall
issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company at each Closing Units
in amounts corresponding with the Subscription Amount set forth on each Buyer's signature page hereto,

 

    1

     

    

 

(b)            Closing
Date. Each Closing of the purchase of Units by the Buyers shall occur either virtually or at the offices of Ortoli Rosenstadt
LLP, 366 Madison Avenue, 3rd Floor, New York, NY 10017, as mandated by the Companuy. The date and time of each Closing
shall be at a time determined by the Company provided that the conditions of Section 6 and 7 have been either satisfied or
waived (the "Closing Date"); provided that in no event shall a Closing Date be after October 30, 2020. As
used herein "Business Day" means any day other than a Saturday, Sunday or other day on which commercial banks
in New York, New York are authorized or required by law to remain closed.

 

(c)            Closing
Date Actions. Subject to the satisfaction of the terms and conditions of this Agreement, on or prior to each Closing Date,
(i) the Buyers shall have (a) delivered to the Company such aggregate proceeds for the Units to be issued and sold to
such Buyer at each respective Closing, (b) entered into an agreement to cancel indebtedness of the Company to such Buyer,
including interest, at a conversion price equal to the Purchase Price, or (c) delivered to the Company adequate consideration
for the Units by any combination of such methods, (ii) the Company shall issue Units which such Buyer is purchasing at each
respective Closing in amounts indicated on such Buyer's signature page hereto, duly executed on behalf of the Company.

 

(d)            Deliveries.
Within five Business Days of this Agreement, the Company shall deliver to each applicable Buyer (i) certificates representing
the Warrants purchased by such Buyer and (ii) certificates representing the Common Stock purchased by each Buyer in Units.

 

2.             BUYER'S
REPRESENTATIONS AND WARRANTIES.

 

Each Buyer, severally
and not jointly, represents and warrants to the Company with respect to only itself that, as of the date hereof and as of each
applicable Closing Date:

 

(a)            Investment
Purpose. The Buyer is acquiring the Securities for its own account for investment only and not with a view towards, or for
resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the Securities
Act; provided, however, that by making the representations herein, such Buyer reserves the right to dispose of the Securities at
any time in accordance with or pursuant to an effective registration statement covering such Securities or an available exemption
under the Securities Act. Such Buyer does not presently have any agreement or understanding, directly or indirectly, with any Person
to distribute any of the Securities.

 

(b)            Accredited
Investor Status. The Buyer is an "Accredited Investor" as that term is defined in Rule 501(a) of Regulation
D.

 

(c)            General
Solicitation. The Buyer is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio.

 

(d)            Experience.
The Buyer, either alone or together with its representatives, has such knowledge, sophistication and experience in business and
financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has
so evaluated the merits and risks of such investment. The Buyer is able to bear the economic risk of an investment in the Securities
and, at the present time, is able to afford a complete loss of such investment.

 

    2

     

    

(e)            Independent
Investment Decision. The Buyer has independently evaluated the merits of its decision to purchase Securities pursuant to the
Transaction Documents, and such Buyer confirms that it has not relied on the advice of any other Buyer's business and/or legal
counsel in making such decision. The Buyer understands that nothing in this Agreement or any other materials presented by or on
behalf of the Company to the Buyer in connection with the purchase of the Securities constitutes legal, tax or investment advice.
The Buyer has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate
in connection with its purchase of the Securities.

 

(f)             Reliance
on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and such Buyer's compliance with, the representations, warranties, agreements, acknowledgments and understandings
of such Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of such Buyer to acquire
the Securities.

 

(g)            Information.
The Buyer and its advisors (and his or its counsel), if any, have been furnished with all materials relating to the business, finances
and operations of the Company and information it deemed material to making an informed investment decision regarding his purchase
of the Securities, which have been requested by such Buyer. The Buyer and its advisors, if any, have been afforded the opportunity
to ask questions of the Company and its management. Neither such inquiries nor any other due diligence investigations conducted
by such Buyer or its advisors, if any, or its representatives shall modify, amend or affect such Buyer's right to rely on the Company's
representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves
a high degree of risk. The Buyer has sought such accounting, legal and tax advice, as it has considered necessary to make an informed
investment decision with respect to its acquisition of the Securities.

 

(h)            Transfer
or Resale. The Buyer understands that: (i) the Securities have not been registered under the Securities Act or any state
securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder,
(B) such Buyer shall have delivered to the Company an opinion of counsel, in a generally acceptable form, to the effect that
such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration
requirements, or (C) such Buyer provides the Company with reasonable assurances (in the form of seller and broker representation
letters) that such Securities can be sold, assigned or transferred pursuant to Rule 144 promulgated under the Securities Act,
as amended (or a successor rule thereto) (collectively, "Rule 144"), in each case following the applicable
holding period set forth therein; and (ii) any sale of the Securities made in reliance on Rule 144 may be made only in
accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under
circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term
is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and
regulations of the SEC thereunder.

 

    3

     

    

 

(i)             Legends.
The Buyer agrees to the imprinting, so long as it is required by this Section 2(f), of a restrictive legend on the Securities
in substantially the following form:

 

THE SECURITIES REPRESENTED
BY THIS CERTIFICATE [AND ANY SECURITIES INTO WHICH IT MAY BE EXERCISED] HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT PURPOSES AND
NOT WITH A VIEW TOWARD RESALE AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR
AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE
SECURITIES LAWS.

 

(j)             Organization;
Authority. Such Buyer, if an entity, is an entity duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents (as defined below) to which it is a party and otherwise to carry out its obligations hereunder and
thereunder.

 

(k)            Authorization,
Enforcement. This Agreement has been duly and validly authorized, executed and delivered on behalf of such Buyer and shall
constitute the legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance with its terms,
except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights
and remedies.

 

(l)             No
Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the consummation by such Buyer of the
transactions contemplated hereby will not (i) result in a violation of the organizational documents of such Buyer, (ii) conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such
Buyer is a party or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal
and state securities laws) applicable to such Buyer, except, in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse
effect on the ability of such Buyer to perform its obligations hereunder.

 

(m)            Brokers
and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or any Buyer for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of the Buyer.

 

(n)            Certain
Trading Activities. The Buyer has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding
with the Buyer, engaged in any transactions in the securities of the Company (including, without limitation, any Short Sales (as
defined below) involving the Company's securities) during the period commencing as of the time that communications regarding the
specific investment in the Company contemplated by this Agreement began and ending immediately prior to the execution of this Agreement
by such Buyer. The Buyer hereby agrees that it shall not directly or indirectly, engage in any Short Sales involving the Company's
securities during the period commencing on the date hereof and ending when no Warrants remain outstanding. For purposes of this
Agreement, "Short Sales" means all "short sales" as defined in Rule 200 promulgated under Regulation
SHO under the 1934 Act (as defined below). The Buyer is aware that Short Sales and other hedging activities may be subject to applicable
federal and state securities laws, rules and regulations and the Buyer acknowledges that the responsibility of compliance
with any such federal or state securities laws, rules and regulations is solely the responsibility of the Buyer.

 

    4

     

    

 

(o)            No
Governmental Review. The Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the Offering.

 

(p)            Regulation
M. The Buyer is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Common
Stock and other activities with respect to the Common Stock by the Buyers.

 

(q)            No
minimum. Each Buyer acknowledges that there is no minimum number of Units that must be sold to conduct a Closing and that the
Buyer could be the sole Buyer under his Agreement. Each Buyer agrees that the Company may conduct multiple Closings under this
Agreement, and the Company is not obligated to conduct more than one Closing under this Agreement.

 

3.             REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.

 

Except as otherwise
set forth in the Company's public filings with the U.S. Securities and Exchange Commission, the Company hereby makes the representations
and warranties set forth below to The Buyer:

 

(a)            Organization
and Qualification. The Company and each of its Subsidiaries are entities duly formed, validly existing and in good standing
under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to own their properties
and to carry on their business as now being conducted and as presently proposed to be conducted. The Company and each of its Subsidiaries
is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property
or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so
qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below). As used
in this Agreement, "Material Adverse Effect" means any material adverse effect on (i) the business, properties,
assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company and
its Subsidiary, taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or
any other agreements or instruments to be entered into by the Company in connection herewith or therewith or (iii) the authority
or ability of the Company to perform any of its obligations under any of the Transaction Documents (as defined below). "Subsidiaries"
means any Person in which the Company, directly or indirectly, owns a majority of the outstanding capital stock having voting power
or holds a majority of the equity or similar interest of such Person, and each of the foregoing, is individually referred to herein
as a "Subsidiary".

 

    5

     

    

 

(b)            Authorization;
Enforcement; Validity. The Company has the requisite power and authority to enter into and perform its obligations under this
Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof. The
execution and delivery of this Agreement and the other Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Securities, and the reservation
for issuance and issuance of the Warrants Shares issuable upon exercise of the Warrants, have been duly authorized by the Company's
board of directors and no further filing, consent or authorization is required by the Company, its board of directors or its stockholders
or other governmental body. This Agreement has been, and the other Transaction Documents to which the Company is a party will be
prior to each Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and binding obligations
of the Company, enforceable against the Company in accordance with its respective terms, except as such enforceability may be limited
by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally, the enforcement of applicable creditors' rights and remedies and except as rights to indemnification
and to contribution may be limited by federal or state securities law. "Transaction Documents" means, collectively,
this Agreement, the Warrants, ancillary documents provided by the Company (which documents may include, without limitation, an
investor acknowledgment letter, a client suitability review questionnaire and an anti-money laundering information form) and each
of the other agreements and instruments entered into by the Company or delivered by the Company in connection with the transactions
contemplated hereby and thereby, as may be amended from time to time.

 

(c)            Issuance
of Securities. The issuance of the Securities are duly authorized and, upon issuance and payment in accordance with the terms
of the Transaction Documents the respective Securities shall be validly issued, fully paid and non-assessable and free from all
preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of first refusal, encumbrances,
security interests and other encumbrances (collectively "Liens") with respect to the issuance thereof. As of each
Closing, the Company shall have reserved from its duly authorized capital stock the maximum number of Warrant Shares. Upon issuance
in accordance with the Warrants, the Warrant Shares, when issued, will be validly issued, fully paid and nonassessable and free
from all preemptive or similar rights or Liens with respect to the issue thereof, with the holders being entitled to all rights
accorded to a holder of Common Stock.

 

(d)            No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Securities, and
the reservation for issuance of the Warrant Shares) will not (i) result in a violation of the Articles of Incorporation (as
defined below), Bylaws (as defined below), certificate of formation, memorandum of association, articles of association, bylaws
or other organizational documents of the Company or any of its Subsidiaries, or any capital stock or other securities of the Company
or any of its Subsidiaries, (ii) conflict with, or constitute a default under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries
is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation,
U.S. federal and state securities laws and regulations, the securities laws of the jurisdictions of the Company's incorporation
or in which it or its subsidiaries operate and the rules and regulations of the OTC QB (the "Principal Market")
and including all applicable laws, rules and regulations of the State of Nevada) applicable to the Company or any of its Subsidiaries
or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of (ii) and
(iii) for any conflict, default, right or violation that would not reasonably be expected to result in a Material Adverse
Effect.

 

    6

     

    

 

(e)            Consents.
The Company is not required to obtain any material consent from, authorization or order of, or make any filing or registration
with (other than any filings as may be required by any state securities agencies, the filing of a Form D with the US Securities
and Exchange Commission and any filings as may be required by the Principal Market), any Governmental Entity (as defined below)
or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations
under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents,
authorizations, orders, filings and registrations which the Company or any Subsidiary is required to obtain pursuant to the preceding
sentence have been or will be obtained or effected on or prior to each applicable Closing Date, and neither the Company nor any
of its Subsidiaries are aware of any facts or circumstances which might prevent the Company or any of its Subsidiaries from obtaining
or effecting any of the registration, application or filings contemplated by the Transaction Documents. The Company is not in violation
of the requirements of the Principal Market and has no knowledge of any facts or circumstances which could reasonably lead to delisting
or suspension of the Common Stock in the foreseeable future. The Company has notified the Principal Market of the issuance of all
of the Securities hereunder, which does not require obtaining the approval of the stockholders of the Company or any other Person
or Governmental Entity, and the Principal Market has completed its review of the related Listing of Additional Share form. "Governmental
Entity" means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature,
federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including
any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization
or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory,
or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned
or controlled by a government or a public international organization or any of the foregoing.

 

(f)            Acknowledgment
Regarding Buyer's Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the capacity
of an arm's length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and
that no Buyer is (i) an officer or director of the Company or any of its Subsidiaries, (ii) to its knowledge, an "affiliate"
(as defined in Rule 144 promulgated under the 1933 Act (or a successor rule thereto) (collectively, "Rule 144"))
of the Company or any of its Subsidiaries or (iii) to its knowledge, a "beneficial owner" of more than 10% of the
shares of Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further represents to each Buyer
that the Company's decision to enter into the Transaction Documents to which it is a party has been based solely on the independent
evaluation by the Company and its representatives.

 

    7

     

    

 

(g)            No
Integrated Offering. None of the Company, its Subsidiaries or any of their affiliates, nor any Person acting on their behalf
has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would cause this offering of the Securities to require approval of stockholders of the Company under any applicable stockholder
approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation
system on which any of the securities of the Company are listed or designated for quotation. None of the Company, its Subsidiaries,
their affiliates nor any Person acting on their behalf will take any action or steps that would cause the offering of any of the
Securities to be integrated with other offerings of securities of the Company.

 

(h)           Application
of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including,
without limitation, any distribution under a rights agreement), stockholder rights plan or other similar anti-takeover provision
under the Articles of Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation
or otherwise which is or could become applicable to any Buyer as a result of the transactions contemplated by this Agreement, including,
without limitation, the Company's issuance of the Securities and any Buyer's ownership of the Securities.

 

(i)             SEC
Documents; Financial Statements. The Company has filed all reports, schedules, forms, proxy statements, statements and other
documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934,
as amended (the "1934 Act") (all of the foregoing filed prior to the date hereof and all exhibits and appendices
included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter
referred to as the "SEC Documents"). As of their respective dates (which in the event of an amended SEC Document,
shall be the date of the last such amendment), the SEC Documents complied in all material respects with the requirements of the
1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the
SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the
SEC Documents complied in all material respects with applicable accounting requirements and the published rules and regulations
of the SEC with respect thereto as in effect as of the time of filing. Such financial statements have been prepared in accordance
with generally accepted accounting principles ("GAAP"), consistently applied, during the periods involved (except
(i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited
interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all
material respects the financial position of the Company as of the dates thereof and the results of its operations and cash flows
for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be
material, either individually or in the aggregate). No other information provided by or on behalf of the Company to any of the
Buyers which is not included in the SEC Documents (including, without limitation, information in the disclosure schedules to this
Agreement) contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the
statements therein not misleading, in the light of the circumstance under which they are or were made. The Company is not currently
contemplating to amend or restate any of the financial statements (including, without limitation, any notes or any letter of the
independent accountants of the Company with respect thereto) included in the SEC Documents (the "Financial Statements"),
nor is the Company currently aware of facts or circumstances which would require the Company to amend or restate any of the Financial
Statements, in each case, in order for any of the Financials Statements to be in compliance with GAAP and the rules and regulations
of the SEC. The Company has not been informed by its independent accountants that they recommend that the Company amend or restate
any of the Financial Statements or that there is any need for the Company to amend or restate any of the Financial Statements.

 

    8

     

    

 

(j)             Absence
of Certain Changes. Since the date of the Company's most recent audited financial statements contained in a Form 10-K,
there has been no material adverse change and no material adverse development in the business, assets, liabilities, properties,
operations (including results thereof), condition (financial or otherwise) or prospects of the Company or any of its Subsidiaries.
Since the date of the Company's most recent audited financial statements contained in a Form 10-K, neither the Company nor
any of its Subsidiaries has (i) declared or paid any dividends, (ii) sold any material assets, individually or in the
aggregate, outside of the ordinary course of business or (iii) made any material capital expenditures, individually or in
the aggregate, outside of the ordinary course of business. Neither the Company nor any of its Subsidiaries has taken any steps
to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation
or winding up, nor does the Company or any Subsidiary have any knowledge or reason to believe that any of their respective creditors
intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor
to do so.

 

(k)            No
Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has occurred
or exists, or is reasonably expected to exist or occur specific to the Company, any of its Subsidiaries or any of their respective
businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that
has not been publicly disclosed and would reasonably be expected to have a Material Adverse Effect. For the avoidance of doubt,
this section shall not relate to any event, liability, development or circumstance that affects other companies in the Company's
industry.

 

(l)             Conduct
of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term under its Articles
of Incorporation, any certificate of designation, preferences or rights of any other outstanding series of preferred stock of the
Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation, memorandum of association,
articles of association, Articles of Incorporation or certificate of incorporation or bylaws, respectively. Neither the Company
nor any of its Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation
applicable to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business
in violation of any of the foregoing, except in all cases for violations which would not reasonably be expected to have a Material
Adverse Effect. Without limiting the generality of the foregoing, the Company is not in violation of any of the rules, regulations
or requirements of the Principal Market and has no knowledge of any facts or circumstances that could reasonably lead to delisting
or suspension of the Common Stock by the Principal Market in the foreseeable future. During the one year prior to the date hereof,
(i) the Common Stock has been listed or designated for quotation on the Principal Market, (ii) trading in the Common
Stock has not been suspended by the SEC or the Principal Market and (iii) the Company has received no communication, written
or oral, from the SEC or the Principal Market regarding the suspension or delisting of the Common Stock from the Principal Market,
which has not been publicly disclosed. The Company and each of its Subsidiaries possess all certificates, authorizations and permits
issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the failure to
possess such certificates, authorizations or permits would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect, and neither the Company nor any of its Subsidiaries has received any notice of proceedings relating
to the revocation or modification of any such certificate, authorization or permit. There is no agreement, commitment, judgment,
injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries
is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice
of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries or the conduct
of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or in the aggregate,
which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of its Subsidiaries.

 

    9

     

    

 

(m)            Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries nor any director, officer, agent, employee, nor any other
person acting for or on behalf of the Company or any of its Subsidiaries (individually and collectively, a "Company Affiliate")
have violated the U.S. Foreign Corrupt Practices Act (the "FCPA”) or any other applicable anti-bribery or anti-corruption
laws, nor has any Company Affiliate offered, paid, promised to pay, or authorized the payment of any money, or offered, given,
promised to give, or authorized the giving of anything of value, to any officer, employee or any other person acting in an official
capacity for any Governmental Entity to any political party or official thereof or to any candidate for political office (individually
and collectively, a "Government Official") or to any person under circumstances where such Company Affiliate knew
or was aware of a high probability that all or a portion of such money or thing of value would be offered, given or promised, directly
or indirectly, to any Government Official, for the purpose, in violation of applicable law, of: (i) (A) influencing any
act or decision of such Government Official in his/her official capacity, (B) inducing such Government Official to do or omit
to do any act in violation of his/her lawful duty, (C) securing any improper advantage, or (D) inducing such Government
Official to influence or affect any act or decision of any Governmental Entity, or (ii) assisting the Company or its Subsidiaries
in obtaining or retaining business for or with, or directing business to, the Company or its Subsidiaries.

 

(n)            Equity
Capitalization.

 

(i)            Definitions:

 

(A)            "Common
Stock" means (x) the Company's shares of common stock, par value $0.001 per share, and (y) any capital stock
into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(B)            "Preferred
Stock" means (x) the Company's blank check preferred stock, par value $0.001 per share, the terms of which may be
designated by the board of directors of the Company in a statement of designations and (y) any capital stock into which such
preferred stock shall have been changed or any share capital resulting from a reclassification of such preferred stock (other than
a conversion of such preferred stock into Common Stock in accordance with the terms of such Certificate of Designations).

 

    10

     

    

 

(ii)           Authorized
and Outstanding Capital Stock. As of the date hereof, the authorized capital stock of the Company consists of (A) 250,000,000
shares of Common Stock, of which, approximately [------------] are issued and outstanding and (B) 100,000,000 shares of Preferred
Stock, of which there are authorized 500,000 shares of Class A Convertible Preferred Stock (227,998 are outstanding) and 1,000,000
shares of Class B Convertible Preferred Stock (503,134 are outstanding) are issued and outstanding.

 

(iii)         Valid
Issuance; Available Shares. All of such outstanding shares are duly authorized and have been validly issued and are fully paid
and nonassessable.

 

(iv)         Existing
Securities; Obligations. Except as disclosed in the SEC Documents: (A) none of the Company's or any Subsidiary's shares,
interests or capital stock is subject to preemptive rights or any other similar rights or Liens suffered or permitted by the Company
or any Subsidiary; (B) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of
any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares,
interests or capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements
by which the Company or any of its Subsidiaries is or may become bound to issue additional shares, interests or capital stock of
the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or
capital stock of the Company or any of its Subsidiaries; (C) there are no agreements or arrangements under which the Company
or any of its Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act (except pursuant to
this Agreement); (D) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain
any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company
or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries; (E) there
are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities;
and (G) neither the Company nor any Subsidiary has any stock appreciation rights or "phantom stock" plans or agreements
or any similar plan or agreement.

 

(v)          Organizational
Documents. The Company has furnished to the Buyers or filed on EDGAR true, correct and complete copies of the Company's Articles
of Incorporation, as amended and as in effect on the date hereof (the "Articles of Incorporation"), and the Company's
bylaws, as amended and as in effect on the date hereof (the "Bylaws"), and the terms of all Convertible Securities
and the material rights of the holders thereof in respect thereto.

 

    11

     

    

 

(o)            Litigation.
Except as disclosed in the SEC Documents, there is no action, suit, arbitration, proceeding, inquiry or investigation before or
by the Principal Market, any court, public board, other Governmental Entity, self-regulatory organization or body pending or, to
the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries, the Common Stock or any of
the Company's or its Subsidiaries' officers or directors, whether of a civil or criminal nature or otherwise, in their capacities
as such, which would reasonably be expected to result in a Material Adverse Effect. After reasonable inquiry of its employees,
the Company is not aware of any event which might result in or form the basis for any such action, suit, arbitration, investigation,
inquiry or other proceeding. Without limitation of the foregoing, there has not been, and to the knowledge of the Company, there
is not pending or contemplated, any investigation by the SEC involving the Company, any of its Subsidiaries or any current or former
director or officer of the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries is the subject of
any order, writ, judgment, injunction, decree, determination or award of any Governmental Entity that would reasonably be expected
to result in a Material Adverse Effect.

 

(p)            Manipulation
of Price. Neither the Company nor any of its Subsidiaries has, and, to the knowledge of the Company, no Person acting on their
behalf has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or manipulation
of the price of any security of the Company or any of its Subsidiaries to facilitate the sale or resale of any of the Securities,
(ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid
or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company or any of
its Subsidiaries.

 

(q)            Registration
Eligibility. The Company is eligible to register the resale of the Shares and the Warrant Shares by the Buyers using Form S-1
promulgated under the 1933 Act, provided that the US Securities and Exchange Commission may require the Company to register the
Warrant Shares in multiple registration statements to avoid an indirect primary offering.

 

(r)             Shell
Company Status. The Company is not an issuer identified in, or subject to, Rule 144(i).

 

(s)            Money
Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act
of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, but not limited to, the
laws, regulations and Executive Orders and sanctions programs ("Sanctions Programs") administered by the U.S.
Office of Foreign Assets Control ("OFAC"), including, without limitation, (i) Executive Order 13224 of September 23,
2001 entitled, "Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism"
(66 Fed. Reg. 49079 (2001)); and any regulations contained in 31 CFR, Subtitle B, Chapter V.

 

    12

     

    

 

(t)             Disclosure.
The Company confirms that neither it nor any other Person acting on its behalf has provided any of the Buyers or their agents or
counsel with any information that constitutes or could reasonably be expected to constitute material, non- public information concerning
the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by this Agreement and the other
Transaction Documents. The Company understands and confirms that each of the Buyers will rely on the foregoing representations
in effecting transactions in securities of the Company. All disclosure provided to the Buyers regarding the Company and its Subsidiaries,
their businesses and the transactions contemplated hereby, including the schedules to this Agreement, furnished by or on behalf
of the Company or any of its Subsidiaries, taken as a whole, is true and correct and does not contain any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. All of the written information furnished after the date hereof by or on behalf of the
Company or any of its Subsidiaries to each Buyer pursuant to or in connection with this Agreement and the other Transaction Documents,
taken as a whole, will be true and correct in all material respects as of the date on which such information is so provided and
will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading. No event or circumstance has occurred
or information exists with respect to the Company or any of its Subsidiaries or its or their business, properties, liabilities,
prospects, operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or
regulation, requires public disclosure at or before the date hereof or announcement by the Company but which has not been so publicly
disclosed. All financial projections and forecasts that have been prepared by or on behalf of the Company or any of its Subsidiaries
and made available to the Buyers have been prepared in good faith based upon reasonable assumptions and represented, at the time
each such financial projection or forecast was delivered to each Buyer, the Company's best estimate of future financial performance
(it being recognized that such financial projections or forecasts are not to be viewed as facts and that the actual results during
the period or periods covered by any such financial projections or forecasts may differ from the projected or forecasted results).
The Company acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 2.

 

(u)            Regulatory
Permits. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct its respective business as currently conducted and
as described in the SEC Documents, except where the failure to possess such permits, individually or in the aggregate, has not
and would not have a Material Adverse Effect ("Material Permits"). Neither the Company nor any of its Subsidiaries
has received any notice of Proceedings relating to the revocation or material adverse modification of any such Material Permits.

 

(v)            Title
to Assets. The Company and its Subsidiaries have good and marketable title in fee simple to all real property owned by them,
if any. The Company and its Subsidiaries have good and marketable title to all tangible personal property owned by them that is
material to the business of the Company and its Subsidiaries, taken as whole, in each case free and clear of all Liens except as
disclosed in Schedule 3.1(o) or such as do not materially affect the value of such property and do not interfere with the
use made and proposed to be made of such property by the Company and any of its Subsidiaries. Any real property and facilities
held under lease by the Company and any of its Subsidiaries are held by them under valid, subsisting and enforceable leases with
such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and facilities
by the Company and its Subsidiaries.

 

(w)            Patents
and Trademarks. To the knowledge of the Company, the Company and its Subsidiaries own, possess, license or have other rights
to use, all patents, patent applications, trade and service marks, trade and service mark applications and registrations, trade
names, trade secrets, inventions, copyrights, licenses, technology, know-how and other intellectual property rights and similar
rights necessary or material for use in connection with their respective businesses as described in the SEC Documents and which
the failure to so have would have a Material Adverse Effect (collectively, the "Intellectual Property Rights").
There is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by any Person that the Company's
business as now conducted infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights
of such Person. To the knowledge of the Company, there is no existing infringement by another Person of any of the Intellectual
Property Rights that would have a Material Adverse Effect. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where failure to do so would
not, individually or in the aggregate, have a Material Adverse Effect.

 

    13

     

    

 

(x)            Insurance.
The Company and each of its Subsidiaries are insured against directors and officers liability by insurers of recognized financial
responsibility against such losses and risks and in such amounts as the Company believes to be prudent and customary in the businesses
and locations in which the Company and the Subsidiaries are engaged. Neither the Company nor any of its Subsidiaries has received
any notice of cancellation of any such insurance, nor, to the knowledge of the Company, will it or any Subsidiary be unable to
renew their respective existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business.

 

(y)            Transactions
with Affiliates and Employees. Except as set forth in the SEC Reports, none of the executive officers or directors of the Company
and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company
or any Subsidiary (other than for services as employees, officers and directors), that would be required to be disclosed pursuant
to Item 404 of Regulation S-K promulgated under the Securities Act.

 

(z)            Sarbanes-Oxley;
Disclosure Controls. Except as disclosed in the SEC Documents, the Company is in compliance in all material respects with all
of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of each applicable Closing Date. The Company
has established disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under
the Exchange Act) for the Company. Since the end of the period covered by the Company's most recently filed periodic report under
the Exchange Act, there have been no changes in the Company's internal control over financial reporting (as such term is defined
in the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company's internal control
over financial reporting.

 

(aa)          FDA.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (the "FDA") under the
Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (the "FDCA") that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company (each such product, a "Product"),
such Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with
all applicable requirements under the FDCA and similar laws, rules and regulations relating to registration, investigational
use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical
practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be
in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the knowledge of the Company, threatened,
Action against the Company, and the Company has not received any notice, warning letter or other communication from the FDA or
any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses
of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Product,
(ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising
or sales promotional materials relating to, any Product, (iii) imposes a clinical hold on any clinical investigation by the
Company, (iv) enjoins production at any facility of the Company, (v) enters or proposes to enter into a consent decree
of permanent injunction with the Company, or (vi) otherwise alleges any violation of any such laws, rules or regulations
by the Company, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business
and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws,
rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale,
license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA
expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the
Company.

 

    14

     

    

 

(bb)         Certain
Fees. No person or entity will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or a Buyer for any commission, fee or other compensation pursuant to any agreement, arrangement
or understanding entered into by or on behalf of the Company, other than legal, accounting and other fees and expenses customary
in similar offerings that are being paid by the Company. The Company shall indemnify, pay, and hold each Buyer harmless against,
any liability, loss or expense (including, without limitation, attorneys' fees and out-of-pocket expenses) arising in connection
with any such right, interest or claim.

 

(cc)          Investment
Company. The Company is not and, immediately after receipt of payment for the Shares and Warrants, will not be an "investment
company" within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a
manner so that it will not become subject to the Investment Company Act of 1940, as amended.

 

(dd)         No
General Solicitation. Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf, has engaged
in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection
with the offer or sale of the Securities.

 

(ee)          Private
Placement. Assuming the accuracy of the Buyers' representations and warranties set forth in Section 2, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Buyers as contemplated hereby.
The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Primary Market.

 

    15

     

    

 

4.             COVENANTS.

 

(a)            Use
of Proceeds. The Company will use the proceeds from the sale of the Securities hereunder for working capital and other general
corporate purposes. Neither the Company nor any Subsidiary will, directly or indirectly, use the proceeds of the transactions contemplated
herein, or lend, contribute, facilitate or otherwise make available such proceeds to any Person (i) to fund, either directly
or indirectly, any activities or business of or with any Person that is identified on the list of Specially Designated Nationals
and Blocker Persons maintained by OFAC, or in any country or territory, that, at the time of such funding, is, or whose government
is, the subject of Sanctions Programs, or (ii) in any other manner that will result in a violation of Sanctions Programs.

 

(b)            Pledge
of Securities. Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges and agrees that
the Securities may be pledged by a Buyer in connection with a bona fide margin agreement or other loan or financing arrangement
that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities
hereunder, and no Buyer effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise
make any delivery to the Company pursuant to this Agreement or any other Transaction Document. The Company hereby agrees to execute
and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities
to such pledgee by a Buyer.

 

(c)            Reservation
of Shares. So long as any of the Warrants remain outstanding, the Company shall take all action necessary to at all times have
authorized, and reserved for the purpose of issuance, no less the maximum number of Warrant Shares issuable upon exercise of all
the Warrants then outstanding (the "Required Reserve Amount"); provided that at no time shall the number of shares
of Common Stock reserved pursuant to this Section 4(g) be reduced other than proportionally in connection with any conversion
and/or redemption, or reverse stock split. If at any time the number of shares of Common Stock authorized and reserved for issuance
is not sufficient to meet the Required Reserved Amount, the Company will promptly take all corporate action necessary to authorize
and reserve a sufficient number of shares, including, without limitation, calling a special meeting of stockholders to authorize
additional shares to meet the Company's obligations pursuant to the Transaction Documents, in the case of an insufficient number
of authorized shares, and obtain stockholder approval of an increase in such authorized number of shares, and voting the management
shares of the Company in favor of an increase in the authorized shares of the Company to ensure that the number of authorized shares
is sufficient to meet the Required Reserved Amount.

 

(e)            Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
including this Agreement, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide
any Buyer or its agents or counsel with any information regarding the Company that the Company believes constitutes material non-public
information without the express written consent of such Buyer, unless prior thereto such Buyer shall have executed a written agreement
regarding the confidentiality and use of such information. The Company understands and confirms that each Buyer shall be relying
on the foregoing covenant in effecting transactions in securities of the Company.

 

(f)             Confidentiality.
Each Buyer, severally and not jointly with the other Buyers, covenants that, until such time as the transactions contemplated by
this Agreement are publicly disclosed by the Company as described in Section 4.5, (i) such Buyer shall maintain the confidentiality
of all disclosures made to it in connection with this transaction, including the existence and terms of this transaction and the
information included in the Transaction Documents, and (ii) neither such Buyer nor any Person acting on its behalf or pursuant
to any understanding with it shall engage in any purchase or sale of securities of the Company (including Short Sales). Notwithstanding
the preceding clause (ii), in the case of a Buyer that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Buyer's assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Buyer's assets, the covenant set forth above shall apply only with
respect to the portion of assets managed by the portfolio manager that has knowledge about the financing transaction contemplated
by this Agreement.

 

    16

     

    

 

(g)            Conduct
of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance or
regulation of any Governmental Entity, except where such violations would not reasonably be expected to result, either individually
or in the aggregate, in a Material Adverse Effect.

 

(h)            Registration
of Securities. Within the later of 10 Business Days of (i) the Company filing with the SEC its interim financial statements
for the period ended August 31, 2020 on Form 10-Q or (ii) the final Closing of this Offering, the Company shall
file a registration statement on Form S-1 with the SEC registering for resale the Common Stock purchased by each Buyer hereunder
as well as the Warrant Shares underlying the Warrants purchased by each Buyer hereunder. At least five Business Days prior to such
filing, the Company may request certain information regarding each buyer of the type required for selling shareholder in a registration
statement on Form S-1, and if a Buyer does not respond with the requested information, the Company may exclude such Buyer
from the registration statement.

 

5.             REGISTER;
TRANSFER AGENT INSTRUCTIONS; LEGEND.

 

(a)            Register.
The Company shall maintain at its principal executive offices or with VStock Transfer, LLC, its transfer agent (or at such other
office or agency of the Company as it may designate by notice to each holder of Securities), a register for the Warrants in which
the Company shall record the name and address of the Person in whose name the Warrants have been issued (including the name and
address of each transferee), the amount of Warrants held by such Person, and the number of Warrant Shares issuable upon exercise
of the Warrants held by such Person. The Company shall keep the register open and available at all times during business hours
for inspection of any Buyer or its legal representatives.

 

(b)            Transfer
Restrictions. The Securities may only be disposed of in compliance with state and federal securities laws. In connection with
any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an
Affiliate of a Buyer or in connection with a pledge as contemplated herein, the Company may require the transferor thereof to provide
to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration
of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing
to be bound by the terms of this Agreement and shall have the rights and obligations of a Buyer under this Agreement.

 

    17

     

    

 

6.             CONDITIONS
TO THE COMPANY'S OBLIGATION TO SELL.

 

The obligation of the
Company hereunder to issue and sell the Units to each Buyer at each Closing is subject to the satisfaction, at or before each applicable
Closing Date, of each of the following conditions, provided that these conditions are for the Company's sole benefit and may be
waived by the Company at any time in its sole discretion by providing each Buyer with prior written notice thereof:

 

(a)            Such
Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Company.

 

(b)            Such
Buyer shall have delivered to the Company the Purchase Price (less, in the case of any Buyer, the amounts withheld pursuant to
Section 4(d)) for the Units being purchased by such Buyer at each applicable Closing by wire transfer of immediately available
funds in accordance with the wire instructions found on Exhibit B and in the amount found on the Signature page hereto.

 

(c)            The
representations and warranties of such Buyer shall be true and correct in all material respects as of the date when made and as
of each applicable Closing Date as though originally made at that time (except for representations and warranties that speak as
of a specific date, which shall be true and correct as of such specific date), and such Buyer shall have performed, satisfied and
complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied
or complied with by such Buyer at or prior to the applicable Closing Date.

 

7.             CONDITIONS
TO EACH BUYER'S OBLIGATION TO PURCHASE.

 

The obligation of each Buyer hereunder
to purchase its Units at each applicable Closing is subject to the satisfaction, at or before each applicable Closing Date, of
each of the following conditions, provided that these conditions are for each Buyer's sole benefit and may be waived by such Buyer
at any time in its sole discretion by providing the Company with prior written notice thereof:

 

(a)            The
Company shall have duly executed and delivered to such Buyer each of the Transaction Documents to which it is a party.

 

(b)            Such
Buyer shall have received the opinion of Ortoli Rosenstadt LLP, the Company's counsel, dated as of each applicable Closing Date
addressed to the Buyer.

 

(c)            Each
and every representation and warranty of the Company shall be true and correct in all material respects (other than representations
and warranties qualified by materiality, which shall be true and correct in all respects) as of the date when made and as of each
applicable Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific
date, which shall be true and correct as of such specific date) and the Company shall have performed, satisfied and complied in
all respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Company
at or prior to each applicable Closing Date, as set forth in section 3 and 4.

 

    18

     

    

 

(d)            The
Common Stock (A) shall be designated for quotation or listed (as applicable) on the Principal Market and (B) shall not
have been suspended, as of each applicable Closing Date, by the SEC or the Principal Market from trading on the Principal Market
nor shall suspension by the SEC or the Principal Market have been threatened, as of each applicable Closing Date, either (I) in
writing by the SEC or the Principal Market or (II) by falling below the minimum maintenance requirements of the Principal
Market.

 

(e)            The
Company shall have obtained all governmental, regulatory or third-party consents and approvals, if any, necessary for the sale
of the Securities, including without limitation, those required by the Principal Market, if any.

 

(g)            No
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions contemplated
by the Transaction Documents.

 

(h)            Since
the date of execution of this Agreement, no event or series of events shall have occurred that has resulted in or would reasonably
be expected to result in a Material Adverse Effect.

 

(i)             The
Company and its Subsidiaries shall have delivered to such Buyer such other documents, instruments or certificates relating to the
transactions contemplated by this Agreement as such Buyer or its counsel may reasonably request.

 

8.             TERMINATION.

 

In the event that a
Closing shall not have occurred with respect to a Buyer by November 30, 2020, then such Buyer shall have the right to terminate
its obligations under this Agreement with respect to itself at any time on or after the close of business on such date without
liability of such Buyer to any other party; provided, however, (i) the right to terminate this Agreement under this Section 8
shall not be available to such Buyer if the failure of the transactions contemplated by this Agreement to have been consummated
by such date is the result of such Buyer's breach of this Agreement and (ii) the abandonment of the sale and purchase of the
Units shall be applicable only to such Buyer providing such written notice, provided further that no such termination shall affect
any obligation of the Company under this Agreement to reimburse such Buyer for the expenses described herein. Nothing contained
in this Section 8 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions
of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any
other party of its obligations under this Agreement or the other Transaction Documents.

 

    19

     

    

 

9.             MISCELLANEOUS.

 

(a)            Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of
the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address
for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by law. Nothing contained herein shall be deemed or operate to preclude any Buyer from bringing suit or taking other legal action
against the Company in any other jurisdiction to collect on the Company's obligations to such Buyer or to enforce a judgment or
other court ruling in favor of such Buyer. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT
TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION
WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(b)            Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that
any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an
executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

(c)            Headings;
Gender. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine,
feminine, neuter, singular and plural forms thereof. The terms "including," "includes," "include"
and words of like import shall be construed broadly as if followed by the words "without limitation." The terms "herein,"
 "hereunder," "hereof" and words of like import refer to this entire Agreement instead of just the provision
in which they are found.

 

(d)            Entire
Agreement, Amendments. This Agreement supersedes all other prior oral or written agreements between the Buyer, the Company,
their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except
as specifically set forth herein or therein, neither the Company nor any Buyer makes any representation, warranty, covenant or
undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in
writing signed by the party to be charged with enforcement.

 

    20

     

    

 

(e)            Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon
receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on
file by the sending party) or electronic mail; or (iii) one (1) Business Day after deposit with an overnight courier
service with next day delivery specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile
numbers and e-mail addresses for such communications shall be:

 

	If to the Company, to:	Q Biomed Inc.
	 	c/o Ortoli Rosenstadt LLP
	 	366 Madison Avenue, 3rd Floor
	 	New York, NY 10017
	 	Telephone: 212-588-0022
	 	Facsimile: 212-826-9307
	 	Attention: William Rosenstadt
	 	Email: wsr@orllp.legal
	 	 
	With Copy to:	Q Biomed Cayman SEZC
	 	Cayman Enterprise City
	 	3rd Floor, South Wing, Flagship Building
	 	Harbour Drive
	 	P.O. Box 10315
	 	Grand Cayman
	 	KY1-1003
	 	Cayman Islands
	 	Attention: Denis Corin
	 	Email: dcorin@qbiomed.com

 

If to a Buyer, to its address, e-mail address
and facsimile number set forth on its signature page hereto.

 

or to such other address, e-mail address
and/or facsimile number and/or to the attention of such other Person as the recipient party has specified by written notice given
to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given
by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the
sender's facsimile machine or e-mail containing the time, date, recipient facsimile number and, with respect to each facsimile
transmission, an image of the first page of such transmission or (C) provided by an overnight courier service shall be
rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause
(i), (ii) or (iii) above, respectively

 

(f)            Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns, including any purchasers of any of the Units (but excluding any purchasers of Underlying Securities, unless pursuant to
a written assignment by such Buyer). The Company shall not assign this Agreement or any rights or obligations hereunder without
the prior written consent of the Buyers. In connection with any transfer of any or all of its Securities, a Buyer may assign all,
or a portion, of its rights and obligations hereunder in connection with such Securities without the consent of the Company, in
which event such assignee shall be deemed to be a Buyer hereunder with respect to such transferred Securities.

 

    21

     

    

 

(g)            Indemnification.

 

(i)            In
consideration of each Buyer's execution and delivery of the Transaction Documents and acquiring the Securities thereunder and in
addition to all of the Company's other obligations under the Transaction Documents, the Company shall defend, protect, indemnify
and hold harmless each Buyer and each holder of any Securities and all of their stockholders, partners, members, officers, directors,
employees and direct or indirect investors and any of the foregoing Persons' agents or other representatives (including, without
limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the "Indemnitees")
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages,
and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification
hereunder is sought), and including reasonable attorneys' fees and disbursements (the "Indemnified Liabilities"),
incurred by any Indemnitee as a result of, or arising out of, or relating to (i) any misrepresentation or breach of any representation
or warranty made by the Company in any of the Transaction Documents, (ii) any breach of any covenant, agreement or obligation
of the Company or any Subsidiary contained in any of the Transaction Documents or (iii) any cause of action, suit, proceeding
or claim brought or made against such Indemnitee by a third party (including for these purposes a derivative action brought on
behalf of the Company or any Subsidiary) or which otherwise involves such Indemnitee that arises out of or results from (A) the
execution, delivery, performance or enforcement of any of the Transaction Documents, (B) any transaction financed or to be
financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or (C) any disclosure
properly made by such Buyer pursuant to Section 4(f), or (D) the status of such Buyer or holder of the Securities either
as an investor in the Company pursuant to the transactions contemplated by the Transaction Documents or as a party to this Agreement
(including, without limitation, as a party in interest or otherwise in any action or proceeding for injunctive or other equitable
relief). To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable
law.

 

(ii)           Promptly
after receipt by an Indemnitee under this Section 9(g) of notice of the commencement of any action or proceeding (including
any governmental action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim in respect thereof
is to be made against the Company under this Section 9(g), deliver to the Company a written notice of the commencement thereof,
and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense
thereof with counsel mutually reasonably satisfactory to the Company and the Indemnitee; provided, however, that an Indemnitee
shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the Company if: (A) the
Company has agreed in writing to pay such fees and expenses; (B) the Company shall have failed promptly to assume the defense
of such Indemnified Liability and to employ counsel reasonably satisfactory to such Indemnitee in any such Indemnified Liability;
or (C) the named parties to any such Indemnified Liability (including any impleaded parties) include both such Indemnitee
and the Company, and such Indemnitee shall have been advised by counsel that a conflict of interest is likely to exist if the same
counsel were to represent such Indemnitee and the Company (in which case, if such Indemnitee notifies the Company in writing that
it elects to employ separate counsel at the expense of the Company, then the Company shall not have the right to assume the defense
thereof and such counsel shall be at the expense of the Company), provided further, that in the case of clause (C) above the
Company shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for the
Indemnitees. The Indemnitee shall reasonably cooperate with the Company in connection with any negotiation or defense of any such
action or Indemnified Liability by the Company and shall furnish to the Company all information reasonably available to the Indemnitee
which relates to such action or Indemnified Liability. The Company shall keep the Indemnitee reasonably apprised at all times as
to the status of the defense or any settlement negotiations with respect thereto. The Company shall not be liable for any settlement
of any action, claim or proceeding effected without its prior written consent, provided, however, that the Company shall not unreasonably
withhold, delay or condition its consent. The Company shall not, without the prior written consent of the Indemnitee, consent to
entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof
the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liability
or litigation, and such settlement shall not include any admission as to fault on the part of the lndemnitee. Following indemnification
as provided for hereunder, the Company shall be subrogated to all rights of the Indemnitee with respect to all third parties, firms
or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the Company
within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnitee
under this Section 9(g), except to the extent that the Company is materially and adversely prejudiced in its ability to defend
such action.

 

    22

     

    

 

(iii)          The
indemnification required by this Section 9(g) shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, within ten (10) days after bills supporting the Indemnified Liabilities are received by the
Company.

 

(iv)          The
indemnity agreement contained herein shall be in addition to (A) any cause of action or similar right of the Indemnitee against
the Company or others, and (B) any liabilities the Company may be subject to pursuant to the law.

 

(h)            No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

[REMAINDER PAGE INTENTIONALLY LEFT BLANK]

 

    23

     

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement to be duly
executed as of the date first written above.

 

	 	COMPANY:
	 	 
	 	Q BIOMED INC.
	 	 
	 	By:	 
	 	Name:	DENIS CORIN
	 	Title:	CEO

 

    24

     

    

 

IN WITNESS WHEREOF, each Buyer and
the Company have caused their respective signature page to this Securities Purchase Agreement to be duly executed as of the
date first written above.

 

 

	 	 	 
	(Subscription Amount - Units)	 	(Name of Buyer – Please type or print)
	 	 	 
	 	 	 
	 	 	 
	(Purchase Price)	 	(Signature and, if applicable, Title)
	 	 	 
	 	 	 
	 	 	(Address of Buyer)
	 	 	 
	 	 	 
	 	 	 
	 	 	(City, State/Province,
	 	 	 
	 	 	Postal Code of Buyer)
	 	 	 
	 	 	 
	 	 	 
	 	 	(Country of Buyer)
	 	 	 
	 	 	Buyer’s Social Security Number/EIN/Corporate Identifier
	 	 	 
	 	 	 

 

Shares to be issued
in:

 

___     Certificated
Form

 

___     Book
Entry (default if no choice made)

 

    25

     

    

 

EXHIBIT A

 

FORM OF WARRANTS

 

    26

     

    

 

EXHIBIT B

 

Q BIOMED INC. WIRE INSTRUCTIONS

 

    27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]